Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema

Clinical trial NCT04618211 · COMPLETED

Trial details

NCT number: NCT04618211
Sponsor: Pharvaris Netherlands B.V.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Hereditary Angioedema Hereditary Angioedema Type I Hereditary Angioedema Type II Hereditary Angioedema Types I and II Hereditary Angioedema Attack Hereditary Angioedema With C1 Esterase Inhibitor Deficiency Hereditary Angioedema - Type 1 Hereditary Angioedema - Type 2 C1 Esterase Inhibitor Deficiency C1 Inhibitor Deficiency

Start date: 2021-02-03
Primary completion: 2022-09-23
Enrollment: 74

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.